Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC-ICI combinations, and global real-world integration.

Journal: Frontiers in immunology •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Wu J (2026). "Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC-ICI combinations, and global real-world integration.". Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1911879